By Malvika Gurung Investing.com -- Shares of the leading oncology pharmaceutical firm Venus Remedies (NS:VENR) were locked in a 5% upper at Rs 251.3 apiece on Thursday after the company...
By Malvika Gurung Investing.com -- Shares of the pharmaceutical company Venus Remedies (NS:VENR) were locked in a 20% upper circuit at Rs 236.75 apiece in Tuesday’s intraday trade,...
By Malvika Gurung Investing.com -- Biocon (NS:BION): The biopharmaceutical company has received an ‘AA+’ rating from CRISIL (NS:CRSL) for its long-term bank facilities on ‘Watch with...
Feb 8 (Reuters) - Venus Remedies Ltd VENR.NS :* VENUS REMEDIES LTD DEC-QUARTER CONSOL NET PROFIT 116.6 MILLION RUPEES VERSUS LOSS 9.6 MILLION RUPEES YEAR AGO* VENUS REMEDIES LTD...
Aug 13 (Reuters) - Venus Remedies Ltd VENR.NS :* JUNE QUARTER LOSS 36.96 MILLION RUPEES VERSUS LOSS 55.6 MILLION RUPEES YEAR AGO* JUNE QUARTER REVENUE FROM OPERATIONS 708.2 MILLION RUPEES...
Feb 14 (Reuters) - Venus Remedies Ltd VENR.NS :* DEC QUARTER NET LOSS 119.3 MILLION RUPEES VERSUS LOSS 42.2 MILLION RUPEES YEAR AGO* DEC QUARTER REVENUE FROM OPERATIONS 690.6 MILLION...
Sept 26 (Reuters) - Venus Remedies Ltd VENR.NS :* GETS SHAREHOLDERS' NOD TO RE-APPOINTMENT MANU CHAUDHARY AS JOINT MANAGING DIRECTOR Source: https://reut.rs/2Ih6oP5 Further company...
May 28 (Reuters) - Venus Remedies Ltd VENR.NS :* MARCH QUARTER LOSS 93.7 MILLION RUPEES VERSUS PROFIT 25.9 MILLION RUPEES YEAR AGO* MARCH QUARTER REVENUE FROM OPERATIONS 932.1 MILLION...
Feb 12 (Reuters) - India's Venus Remedies Ltd VENR.NS :* DEC QUARTER PROFIT 5.4 MILLION RUPEES VERSUS LOSS 21 MILLION RUPEES YEAR AGO* DEC QUARTER REVENUE FROM OPERATIONS 931.3...
Jan 19 (Reuters) - Venus Remedies Ltd VENR.NS :* SAYS WITHDRAWS PRESENT QIP ISSUE
Jan 15 (Reuters) - Venus Remedies Ltd VENR.NS :* INFORMS QIBS ABOUT DECLARATION OF CO AND DIRECTORS AS 'WILFUL DEFAULTERS' BY EXPORT-IMPORT BANK OF INDIA* GIVES FIVE DAYS TO QIBS...
Jan 10 (Reuters) - Venus Remedies Ltd VENR.NS :* SAYS APPROVED QIP ISSUE PRICE 103.65 RUPEES PER SHARE...
Jan 9 (Reuters) - Venus Remedies Ltd VENR.NS :* TO CONSIDER ISSUE PRICE FOR QIP ISSUE...
Jan 8 (Reuters) - Venus Remedies Ltd VENR.NS :* SAYS FLOOR PRICE FOR QIP ISSUE IS 103.64 RUPEES PER EQUITY SHARES...
Dec 7 (Reuters) - India's Venus Remedies Ltd VENR.NS :* SEPT QUARTER NET PROFIT 9.53 MILLION RUPEES VERSUS PROFIT 7.94 MILLION RUPEES YEAR AGO* SEPT QUARTER REVENUE FROM OPERATIONS...
Sept 1 (Reuters) - Venus Remedies Ltd VENR.NS* June quarter profit 8.5 million rupees versus profit 12.4 million rupees year ago* June quarter total income 783.5 million rupees versus 1.03...
March 22 (Reuters) - Venus Remedies Ltd VENR.NS* Gets members' nod for issue & allotment of shares worth 250 million rupees via QIP Source text: Further company coverage:...
March 15 (Reuters) - Venus Remedies Ltd VENR.NS * To consider allotment of 900,000 equity shares on conversion of fully convertible warrants to promoters on preferential basis Source...
Feb 27 (Reuters) - Venus Remedies Ltd VENR.NS * Seeks members' nod for issue of equity shares via QIP for qualified institutional buyers Source text: Further company coverage:...
Feb 22 (Reuters) - Venus Remedies Ltd VENR.NS : * Says recommended further issue of equity capital up to 250 million rupees via QIP Source text: Further company coverage:...
Feb 17 (Reuters) - Venus Remedies Ltd VENR.NS * Says to consider and approve raising of funds by way of qualified institutional placement Source text - Further company coverage:...
Feb 8 (Reuters) - Venus Remedies Ltd VENR.NS :* Dec quarter net loss 21.03 million rupees versus loss 2.54 million rupees year ago* Dec quarter net sales 844.9 million rupees versus 966.8...
Nov 18 (Reuters) - Venus Remedies Ltd VENR.NS * Sept quarter net profit 11.4 million rupees versus profit 16.1 million rupees year ago * Sept quarter net sales 1.07 billion rupees versus...
Aug 14 (Reuters) - Venus Remedies Ltd VENR.NS :* India's Venus Remedies Ltd VENR.NS says June-quarter net profit 1.93million rupees versus 102.5 million rupees* India's Venus...
June 22 (Reuters) - Venus Remedies Ltd VENR.NS :* To consider issue of fully convertible warrants / equity shares to promoterson a preferential...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
